Guggenheim Capital LLC Agios Pharmaceuticals, Inc. Transaction History

Guggenheim Capital LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$33.21 - $46.54 $1.64 Million - $2.31 Million	-49,530 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$33.87 - $55.93 $190,010 - $313,767	-5,610 Reduced 10.17%	49,530 $1.73 Million
Q2 2020 Aug 14, 2020	BUY	$34.45 - $53.48 $217,310 - $337,351	6,308 Added 12.92%	55,140 $2.95 Million
Q1 2020 Jun 02, 2020	SELL	$31.52 - $53.81 $301,961 - $515,499	-9,580 Reduced 16.4%	48,832 $1.73 Million
Q4 2019 Feb 14, 2020	BUY	$30.08 - $50.59 $168,748 - $283,809	5,610 Added 10.62%	58,412 $2.79 Million
Q3 2019 Nov 14, 2019	BUY	$32.4 - $49.58 $172,432 - $263,864	5,322 Added 11.21%	52,802 $1.71 Million
Q2 2019 Aug 14, 2019	SELL	$46.17 - $68.1 $11,542 - $17,025	-250 Reduced 0.52%	47,480 $2.37 Million
Q1 2019 May 15, 2019	SELL	$45.92 - $67.67 $44,450 - $65,504	-968 Reduced 1.99%	47,730 $3.22 Million
Q4 2018 Feb 14, 2019	SELL	$42.73 - $76.53 $123,105 - $220,482	-2,881 Reduced 5.59%	48,698 $2.25 Million
Q3 2018 Nov 14, 2018	BUY	$71.67 - $91.95 $392,034 - $502,966	5,470 Added 11.86%	51,579 $3.98 Million
Q2 2018 Aug 14, 2018	SELL	$73.22 - $99.55 $213,436 - $290,188	-2,915 Reduced 5.95%	46,109 $3.88 Million
Q1 2018 May 15, 2018	SELL	$59.83 - $86.53 $122,053 - $176,521	-2,040 Reduced 3.99%	49,024 $4.01 Million
Q4 2017 Feb 14, 2018	SELL	$52.12 - $72.33 $553,097 - $767,565	-10,612 Reduced 17.21%	51,064 $2.92 Million
Q3 2017 Nov 14, 2017	BUY	$54.89 - $67.12 $3.39 Million - $4.14 Million	61,676	61,676 $4.12 Million

232

58.1M

403K

469K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $3.05B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.